02:12 PM EST, 11/26/2024 (MT Newswires) -- ALT5 Sigma ( ALTS ) said Tuesday it entered a preliminary agreement to acquire Soin Bioscience.

The acquisition, intended to benefit its subsidiary Alyea Therapeutics, will grant Alyea access to Soin's innovative pain medication technology.

A definitive agreement will be contingent on due diligence and other customary conditions, according to the company.

Price: 2.07, Change: -0.05, Percent Change: -2.55